“We’re not trying to be everything for everyone. Our specialized focus has been very exciting for me.”

Franco Negron, CEO of Simtra BioPharma Solutions, has transformed a 65-year sterile manufacturing legacy into an independent CDMO since the company’s carve-out from Baxter International (Baxter) in October 2023. Franco has led over $500 million in capital investments to double capacity and create mirrored capabilities across sites in Indiana, US, and Halle/Westfalen, Germany.

Franco brings industry experience from Procter & Gamble, Johnson & Johnson, Novartis, and Patheon, which became part of Thermo Fisher Scientific, where he helped shape integrated CDMO strategies.

In this PharmaSource podcast, recorded at CPHI 2025, Franco explains how Simtra is navigating supply chain challenges, tariff uncertainties, and injectable manufacturing complexity, from GLP-1s to antibody drug conjugates.

Read more.

“Process chemistry alone is no longer the whole story—it needs to be connected with engineering solutions, digital tools, and data utilization.”

Stefan Randl, Chief Scientific Officer at Siegfried, joined the Swiss-based CDMO in January 2025 after 16 years at Evonik, where he led innovation management for healthcare, ran drug substance operations in the US, and headed sales across Asia.

Read more.

“Biotechs need flexibility and have limited budgets, while big pharma looks for long-term partnerships, reliability, scalability, and new technologies.”

Luis Berrade, Senior Director of Global Biologics Testing Sales at Charles River Laboratories, has spent his career helping pharmaceutical and biotech companies bring therapies to market faster and safer. With a PhD in medicinal chemistry and experience spanning both contract manufacturing and testing services, Luis now leads Charles River’s global biologics testing commercial strategy, working with companies of all sizes to navigate the complex regulatory landscape.

In an episode of the PharmaSource podcast, Luis shares his insights on when sponsors should start thinking about testing strategy, common mistakes that create bottlenecks, and how emerging technologies like next-generation sequencing are reshaping the biologics testing landscape.

Read more.

PharmaSource analysis of 732 industry announcements reveals massive investment in U.S. capacity, with partnerships dominating the news cycle and advanced therapy manufacturing reaching industrial scale

The pharmaceutical contract manufacturing landscape underwent a fundamental readjustment in 2025, marked by record investment flows, accelerated U.S. reshoring, and a decisive shift toward integrated technology platforms.

In this episode, PharmaSource's very own Tamnna Thakur sits down with Editor Dora Wells to break down the year's most significant trends. From the $18.48 billion that poured into U.S. facilities to WuXi Biologics' 20 announcements despite regulatory headwinds. They analyze what the 732 tracked announcements reveal about where the industry is heading.

Read more.

“Twenty years ago, who knew that ADCs and next-generation bioconjugates were going to be so exciting, so successful?”

Campbell Bunce, Chief Scientific Officer at Abzena, reflects on the strategic positioning that has placed his company at the forefront of one of pharma’s fastest-growing segments.

Campbell leads a global team spanning discovery, development, and GMP manufacturing at Abzena, where he has spent nearly a decade building the company’s capabilities in complex modalities. His background as an immunologist, combined with 18 years in biotech before joining Abzena, gives him a unique perspective on translating scientific innovation into commercial manufacturing reality.

In this conversation on the PharmaSource podcast, Campbell discusses Abzena’s strategic focus on antibody-drug conjugates (ADCs) and bioconjugates, the company’s approach to proprietary platform development, and how the CDMO is responding to increased demand driven by geopolitical manufacturing shifts and clinical successes in the space.

Read more.

“When I walked into the tech transfer, we were a million dollars over budget, six months behind schedule, and struggling to make a single successful batch,” says Amy Gamber.

Amy Gamber, Executive Director, Lifecycle Lead at Kyverna Therapeutics, specializes in crisis recovery for late-stage biotech and cell and gene therapy programs. With 20+ years of CMC leadership experience at Atara Biotherapeutics, CSL Seqirus, and Amgen, she’s built a career fixing what others couldn’t.

In this PharmaSource podcast interview, Amy shares how to identify warning signs before minor issues become million-dollar problems, strategies for rescuing failing tech transfers, and what it takes to restart a manufacturing facility dormant for two years.

Full article

“We have to be transparent down to the last person in the organization, what the organization is doing, and where the issues are. We have to celebrate wins. We have to talk about the good things people do.”

Markus Sieger serves as CEO of Polpharma Group, one of Central and Eastern Europe’s largest pharmaceutical manufacturers. With 25 years at the company, and 10 years as CEO, he has transformed the Polish generic and OTC medicines manufacturer into a regional powerhouse producing 400 million packages annually across Poland, Kazakhstan, and Western European markets. Markus will step down as CEO of Polpharma Group in January 2026, transitioning to the company’s supervisory board.

In this conversation, Markus reflects on building Polpharma’s market leadership through culture transformation and digital-first operations, the challenges that shaped his leadership journey, and the evolution of Europe’s generic medicines industry.

Read more.

“Our goal is to be recognized for exceptional reliability in our services and manufacturing, while helping our customers bring the most innovative medicines to market.”

Dr. Michael Quirmbach, CEO and President of CordenPharma, has overseen remarkable growth at the full-service CDMO since joining in 2014. Under his leadership, the company has tripled its workforce to 3,000 employees and increased revenue from €245 million to nearly €1 billion while expanding capabilities across peptides, injectables, and high-potency oncology products.

Michael, who holds a PhD in chemistry and began his career as a scientist before transitioning to business leadership, brings 25 years of CDMO experience to his role. In a recent PharmaSource podcast recorded at CPHI, he discussed CordenPharma’s €900 million expansion in peptide manufacturing, the company’s strategy for complex modalities, and how AI is transforming pharmaceutical manufacturing operations.

Read more.